selenite

Small moleculeexperimental

The selenite anion is a selenium oxoanion with the chemical formula SeO2−3. A selenite (Se) is a compound that contains this ion. Sodium selenite is an inorganic form of the trace element selenium with potential antineoplastic activity. It was documented that Se deficiency observed in some countries and/or geographic regions (e.g. Keshan region in China), is associated with an increased morbidity and mortality of neoplastic diseases. To correct this problem a number of organic and inorganic selenium compounds were developed and tested. However, it is now firmly established that only an inorganic sodium selenite with four-valent Se, and not that with six-valent (selenate) cation shows anticancer activity. Selenite can undergo redox reaction, for example with protein's sulfhydryl groups expressed on the surface of tumor cells. In this way selenite prevents non-enzymatic formation of parafibrin that coats tumors cells and hence presents them as 'self' to the innate cellular immune system. Consequently, macrophages of the lymphatic system do not recognize neoplastic cells as 'foreign' bodies and spare them from the immune destruction. Sodium selenite also showed promise as a cost-effective, nontoxic anti-inflammatory agent. Treatment with sodium selenite lowers reactive oxygen species (ROS) production, causes a spontaneous reduction in lymphedema volume, increases the efficacy of physical therapy for lymphedema, and reduces the incidence of erysipelas infections in patients with chronic lymphedema. Limited evidence has been presented though that intakes of selenium greater than the amount needed to allow full expression of selenoproteins may have chemopreventive effects against cancer. Controlled intervention studies are needed to fully evaluate selenium as a cancer chemopreventive agent. The US Food and Drug Administration approved a selenium supplement to animal diets; the most common form is sodium selenite for pet foods. — NCATS

Clinical trial activity

4 trials · 11 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Feb 1, 2015 (NCT02377635)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Loading structure…

SMILES

[O-][Se]([O-])=O
Mol. weight
126.96 g/mol

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • anhydrous selenite
  • sodium selenite anhydrous
  • sodium selenite pentahydrate

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05451576N/AAug 12, 2020Chang Gung University
NCT04296578Phase 1Jul 31, 2020Stanford University
NCT04201561Phase 3Dec 24, 2019Boryung Pharmaceutical Company, Seoul National University
NCT02377635Phase 1/Phase 2 (Phase 2)Feb 1, 2015Applied Speciation and Consulting LLC, Emory University, University of Alberta, University of Calgary, University of Chicago, University of Saskatchewan, Wagner College
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (11)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Applied Speciation and Consulting LLCFor profit1012015
Boryung Pharmaceutical CompanyFor profit1012019
Chang Gung UniversityAcademic/Hospital1112020
Emory UniversityAcademic/Hospital1012015
Seoul National UniversityAcademic/Hospital1112019
Stanford UniversityAcademic/Hospital1112020
University of AlbertaAcademic/Hospital1012015
University of CalgaryAcademic/Hospital1012015
University of ChicagoAcademic/Hospital1012015
University of SaskatchewanAcademic/Hospital1112015
Wagner CollegeAcademic/Hospital1012015
11 organizations
Page 1 / 1